舒肝解郁胶囊治疗首发精神分裂症急性期的疗效观察

Study on Curative Effect of Shugan Jieyu Capsule in Treatment of Schizophrenia in Acute Phase

目的:观察疏肝解郁胶囊治疗首发精神分裂症急性期的临床疗效。方法:选取2013年1月—2015年1月医院收治的首发精神分裂症急性期患者76例作为研究对象,随机分为观察组38例,对照组38例。对照组:给予利培酮口服液治疗。观察组:给予利培酮口服液联合疏肝解郁胶囊治疗。比较两组患者临床疗效、PANSS、PANSS-EC与CGI-SI评分、依从性及不良反应的变化。结果:观察组总有效率94.2%与对照组总有效率89.5%比较,差异无统计学意义(P>0.05)。与治疗前比较,治疗后7 d及14 d两组患者PANSS、PANSS-EC及CGI-SI评分均降低,但是治疗后两组患者PANSS、PANSS-EC及CGI-SI评分比较,差异无统计学意义(P>0.05)。治疗14 d,观察组患者治疗依从性高于对照组,差异有统计学意义(P<0.05)。两组患者不良反应比较,观察组患者失眠、焦虑及EPS发生率高于对照组。而便秘、嗜睡、心动过速、唾液增多及肝功异常发生率低于对照组,差异有统计学意义(P<0.05)。结论:舒肝解郁胶囊治疗首发精神分裂症急性期患者疗效显著,能够有效降低患者PANSS、PANSS-EC及CGI-SI评分,提高患者治疗依从性,降低患者嗜睡、心动过速及肝功异常等不良反应发生率。

Objective： To observe the curative effect of Shugan Jieyu Capsule in the treatment of schizophrenia in acute phase. Methods： 76 cases of acute phase of the first episode of schizophrenia were selected as the research object from January 2013 to January 2015 in our hospital and were randomly divided into observation group 38 cases and control group 38 cases. Control group： treated with risperidone oral liquid. The observation group： given Risperidone Oral Solution combined with Shugan Jieyu Capsule. We compared the clinical efficacy,PANSS,PANSS- EC and CGI- SI score,compliance and adverse reactions in the two groups. Results The total effective rate of the observation group was 89. 5% and the control group＇s was 94. 2% and the difference was not statistically significant（ P〈0. 05）. Compared with those before treatment,patients＇ PANSS,PANSS- EC and CGI- SI scores were decreased in the two groups after treatment 7 d and 14 d. However,after treatment,patients＇ PANSS,PANSS- EC and CGI- SI scores were compared in the two groups and the difference was not statistically significant（ P〈0. 05）. Treatment for 14 d,the compliance of patients in the observation group was higher than the control group＇s and the difference was statistically significant（ P〈0. 05）. The adverse reactions,insomnia,anxiety and EPS incidence in the observation group were higher than those of the control group. And constipation,lethargy,tachycardia speed,saliva increased and the incidence of abnormal liver function in observation group were lower than those in the control group and the difference was statistically significant（ P〈0. 05）. Conclusion： Shugan Jieyu Capsule in the treatment of schizophrenia in acute phase has good curative effect and can effectively reduce the PANSS,PANSS- EC and CGI- SI scores,improve the treatment compliance of patients and reduce sleepiness,heart rate and abnormal liver function adverse reaction rate.